This is exciting. Human trials using lithium orotate are starting in the spring of 2026 at MGH/Brigham hospital in Boston.
(Lithium orotate is already available as a dietary supplement in the USA.)
Quoted:
But he was always bothered by a missing link in what came to be known as the amyloid hypothesis of Alzheimer’s disease: Some people can have brains riddled with amyloid plaques and have relatively intact cognition, while others who have similar amounts of amyloid are severely impaired.
The recent findings provide a potential explanation. By showing that amyloid binds to and neutralizes lithium, and that aging individuals can vary in their baseline lithium levels, Yankner’s team may be starting to understand the imperfect correlation between amyloid and disease symptoms.
It was a finding 10 years in the making. It required overcoming several technological hurdles, such as the ability to detect very low levels of a metal not previously thought to exist naturally in the body; the development of mouse models that could demonstrate the impact of a loss of lithium in the brain; and the creation of a new screening platform to test a series of lithium compounds to find those that can evade lithium binding.
Quoted:
Still, he is collaborating with researchers at Mass General and Brigham and Women’s Hospital on a clinical trial of lithium orotate, which is expected to begin this spring.
“Hopefully, in the not-too-distant future, we will have some objective data about the efficacy and safety of lithium orotate”, he said. “Many people are waiting for this.”


